BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Besides imatinib and dasatinib, in recent years several new-generation BCR::ABL1-directed TKIs have been developed primarily for patients with chronic myeloid leukemia (CML), including nilotinib, bosutinib, ponatinib, and olverembatinib, and the specifically targeting ABL myristoyl pocket (STAMP) inhibitor asciminib.